Login

Cancer Genetics

OncoMap130 – Precision Oncology for Solid Tumors

130 Genes for Solid Tumor Profiling + Standard of Care Pharmacogenomic Testing for Drug Metabolism and Detoxification

Turn Your Tumor Profile Into a Treatment Plan.

This comprehensive 130-gene panel detects clinically actionable mutations across solid tumors—including lung, breast, colorectal, prostate, and ovarian cancers—supporting precision therapies and clinical trial enrollment. In addition, it incorporates widely recognized pharmacogenetic markers such as DPYD, TPMT, and NUDT15 to help prevent severe treatment-related toxicities.

Order Test
Talk to a Genetic Counselor

What is the OncoMap130 Test?

OncoMap130 analyzes 130 genes known to drive solid tumors, providing a comprehensive view of your tumor’s genetic profile. The test connects these findings to approved targeted therapies, immunotherapies, and relevant clinical trials, supporting precision treatment decisions. In addition, OncoMap130 includes key pharmacogenetic markers—such as DPYD, TPMT, UGT1A1, and NUDT15—to help predict and prevent severe drug-related toxicities, enhancing both treatment efficacy and patient safety.

The OncoMap130 also includes all clinically validated MSI markers — BAT-25, BAT-26, NR-21, NR-22, NR-24, NR-27, MONO-27, D2S123, D5S346, and D17S250 — ensuring accurate detection of microsatellite instability across colorectal, endometrial, gastric, and other solid tumors. MSI status is a critical biomarker for guiding immunotherapy decisions.

Who benefits most from this test:

  • Patients with past drug side effects
  • People on multiple medications
  • Those starting treatment for heart disease, depression, cancer, or chronic pain
  • Providers managing complex cases

Why This Test Matters

For Patients & Families

  • Identify inherited cancer risks early.

  • Take preventive steps such as enhanced screening or lifestyle changes.

  • Share results with relatives for family‑wide health planning.

For Providers

  • Improve patient care with genetic insights.

  • Guide referrals, screening protocols, and preventive interventions.

  • Support cascade testing for at‑risk family members.

For Proactive Consumers

  • Even without a family history, you may carry mutations that increase cancer risk.

  • Knowledge empowers you to take control of your health.

Cancer types covered

Non-Small Cell Lung Cancer (NSCLC)

Colorectal Cancer

Breast Cancer

Melanoma

Ovarian and Endometrial Cancers

Thyroid and Gastric Cancers

Other solid tumors

 Key genes covered

Actionable genes

ALK, BRAF, EGFR, ERBB2 (HER2), KRAS, MET, NTRK1/3, PIK3CA, RET, ROS1, DDR2, FGFR4, ERG Fusions, KIT, BRCA1, BRCA2, TP53, PTEN, NRAS, CTNNB1, MTOR, FGFR1, JAK2

PHARMACOGENETIC MARKERS

DPYD, TPMT, NUDT15, UGT1A1, ERCC1, ERCC2, TYMS, TYMSOS, MTHFR

MICROSATELITE INSTABILITY (MSI) SITES

BAT-25, BAT-26, NR-21, NR-24, MONO-27, D2S123, D5S346,  D17S250

Melanoma

Ovarian and Endometrial Cancers

Thyroid and Gastric Cancers

Other solid tumors

SEE FULL GENE LIST

Our OncoMap 130 panel provides complete exon coverage ensuring detection of SNV, InDels, CNVs, and structural variants across the full coding regions of the genes below:

ALK1, ALK, APC, AR, ARID1A, ARID2, ATM, ATR, ATRX, B2M, BAP1, BARD1, BMPR1A, BRAF, BRCA1, BRCA2, BRIPQ, CBL, CCND1, CD274, CDH1, CDK12, CDK4, CDK6, CDKN2A, CDKN2B, CHEK1, CHEK2, CREBBP, CTNNB1, DDR2, EGFR, EIF1AX, EMSY, EPCAM, ERBB2, ESR1, FAM123B, FAM175A, FANCA, FANCL, FGF19, FGF3, FGF4, FGFR1, FGFR2, FGFR3, FH, FLCN, FLT3, FOXA1, FRG1B, GNA11, GNAQ, GREM1, HOXB13, HRAS, IDH1, IDH2, JAK1, JAK2, KDM5C, KDR, KEAP1, KIT, KRAS, MAP2K1, MDM2, MDM4, MET, MLH1, MRE11A, MSH2, MSH6, MTOR, MUTYH, MYC, NBN, NF1, NOTCH2, NRAS, NRG1, NTRK1, NTRK2, NTRK3, PALB2, PBRM1, PDCD1, PDGFRA, PDGFRB, PIK3CA, PMS1, PMS2, POLD1, POLE, PPP2R2A, PTCH1, PTEN, PAD50, RAD51B, RAD51C, RAD51D, RAD54L, RAF1, RB1, RET, ROS1, SDHA, SDHB, SDHC, SDHD, SETD2, SMAD4, SMARCA4, SOX2, SPOP, STK11, TCEB1, TERT, TFE3, TFEB, TP53, TSC1, TSC3, VEGFA, VHL

What you will learn from this test

  • Which mutations are driving your cancer
  • Targeted therapy options based on your genetic profile
  • Eligibility for immunotherapies
  • Clinical trials that may be available
  • Insights into drug metabolism and pharmacogenetic markers to help prevent severe chemotherapy-related toxicities

Why choose this OncoMap130?

  • 130 gene solid tumor panel with actionable results
  • Actionable results tied to treatment guidelines
  • Clinical-grade reporting for oncologists
  • More affordable than international labs

How it works

Test ordered through your oncologist or provider

Provide a tumor tissue or biopsy sample

Receive a secure report with treatment recommendations

Pricing

Order Your OncoMap130 Test Today

For hematologic and myeloid cancers consider the OncoMap90 (90 genes)

OncoMap50 Test

₦855,000

(For Provider)

Order Test

OncoMap50 Test

₦900,000

(Direct-to-Consumer)

Order Test